Côd QR

Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Minghui Li, Weihua Cao, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Lu Zhang, Yao Lu, Min Chang, Ruyu Liu, Xiaoyan Ding, Ge Shen, Yuanjiao Gao, Hongxiao Hao, Xiaoxue Chen, Leiping Hu, Mengjiao Xu, Yuyong Jiang, Wei Yi, Yao Xie, Rui Song
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2024-06-01
Cyfres:Biosafety and Health
Pynciau:
Ursodeoxycholic acid (UDCA)
Autoimmune liver disease (AILD)
Coronavirus disease 2019 (COVID-19)
Primary biliary cholangitis (PBC)
Autoimmune hepatitis (AIH)
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S2590053624000545
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg